Aging and Hematologic Disorders: Exploring the Evidence
Older adults represent the growing majority of patients diagnosed with hematologic disorders yet remain under-represented on clinical trials. These patients often present with unique treatment challenges and variable clinical trajectories. Important considerations among older patients, such as treatment tolerance and physiologic reserve, cross many different disease- and treatment-specific challenges. This educational session will explore the evidence for best practices for assessing and managing older adults with hematologic disorders including a focus on use of geriatric assessment measures to personalize care. Last, the session will discuss strategies to facilitate optimal trial design to generate evidence reflective of patients seen in practice inclusive of those with comorbidity and frailty.
Dr. Heidi Klepin will outline the evidence for use of geriatric and frailty assessment in hematologic malignancies to inform treatment decision making and management. She will discuss implementation challenges, effectiveness of identifying and intervening upon geriatric deficits, and the impact on clinical decision-making. This talk will outline strategies by which use of geriatric assessment can enhance the quality of health care delivery (e.g. decision-making, patient experience, healthcare utilization) for older adults through provision of personalized care.
Dr. Rebecca Olin will discuss the challenge of providing intensive therapies for older adults including optimized patient selection and toxicity mitigation. Focusing on AML induction chemotherapy and stem cell transplantation, she will discuss the application of available data for use of geriatric measures in patient evaluation and management. Using a case-based approach, Dr. Olin will suggest best practices in areas with limited data.
Dr. Paul Hamlin will discuss the opportunities and challenges inherent to design of trials for older adults. He will provide examples of successful design, development and implementation of clinical trials with clinical endpoints relevant to older adults. This talk will address strategies to both understand treatment effects in older adults and explore methodology to accelerate clinical trial enrollment on a larger scale.
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members